QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-volitionrx-maintains-25-price-target

Cantor Fitzgerald analyst Ross Osborn reiterates VolitionRX (AMEX:VNRX) with a Overweight and maintains $2.5 price target.

 ef-hutton-maintains-buy-on-volitionrx-maintains-45-price-target

EF Hutton analyst Tim Moore maintains VolitionRX (AMEX:VNRX) with a Buy and maintains $4.5 price target.

 volitionrx-q1-2024-gaap-eps-010-beats-011-estimate-sales-171535k-miss-389500k-estimate

VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9...

 cantor-fitzgerald-reiterates-overweight-on-volitionrx-maintains-25-price-target

Cantor Fitzgerald analyst Ross Osborn reiterates VolitionRX (AMEX:VNRX) with a Overweight and maintains $2.5 price target.

 ef-hutton-maintains-buy-on-volitionrx-maintains-45-price-target

EF Hutton analyst Tim Moore maintains VolitionRX (AMEX:VNRX) with a Buy and maintains $4.5 price target.

 volitionrx-q4-eps-011-inline-sales-24397k-miss-45000k-estimate

VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 15.38...

 volitionrx-cash-and-cash-equivalents-as-of-december-31-2023-totaled-207m

Financial HighlightsCash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9...

 earnings-scheduled-for-march-25-2024

Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly loss at $0.08 per share on re...

 earnings-outlook-for-volitionrx
Earnings Outlook For VolitionRX
03/22/2024 14:01:49

 volition-issues-business-review-2023-outlining-its-key-highlights-from-the-past-year

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023...

 why-trinity-place-holdings-shares-are-trading-higher-by-80-here-are-20-stocks-moving-premarket

Shares of Trinity Place Holdings Inc. (NYSE: TPHS) rose sharply in pre-market trading. The company reported in 8K Filing, mor...

 ef-hutton-reiterates-buy-on-volitionrx-maintains-45-price-target

EF Hutton analyst Tim Moore reiterates VolitionRX (AMEX:VNRX) with a Buy and maintains $4.5 price target.

 reported-earlier-volitionrx-says-on-dec-29-received-13m-in-milestone-payments-from-heska-post-license-and-supply-deal-entered-into-on-march-28-2022

- SEC Filing  On December 29, 2023, VolitionRx Limited (the "Company")  received $13.0 million in milestone payments fr...

 volitionrx-secures-55m-in-belgium-regional-government-financing-from-wallonie-entreprendre

 VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION